Cizzle Bio is attending the 17th Annual Next Generation Dx Summit from August 18–20, 2025, in Washington, D.C. We look forward to engaging with global leaders in diagnostics and sharing insights on early detection through biomarker-based innovation.

Cizzle Bio is attending the 8th Annual AABIP Conference in Austin, TX on August 14–16, 2025. We’ll be connecting with leaders in interventional pulmonology to discuss our biomarker blood tests, CIZ1B for lung cancer and DEX-G2 for gastric cancer.

Cizzle Bio will attend the 2025 BIO International Convention in Boston, June 16–19. Meet with our team to learn how our biomarker blood tests are transforming early cancer detection.

Cizzle Bio is proud to announce our attendance at the 2025 ASCO Annual Meeting, taking place from May 30 to June 3, 2025, at McCormick Place, Chicago. This premier oncology event offers a global platform to explore innovations, engage with researchers, and advance our mission of early cancer detection.

Cizzle Bio is excited to attend the AACR Annual Meeting 2025, taking place from April 25-30 at McCormick Place, Chicago. This leading event brings together the brightest minds in cancer research and diagnostics. Learn more about why we’re attending.

Cizzle Bio is excited to attend the 2025 BIO CEO & Investor Conference, a premier event for biotech executives, investors, and industry experts. Taking place on February 10-11, 2025, in New York, this event offers valuable networking opportunities and insights into the latest biotech innovations.

Cizzle Bio is attending the 2025 ASCO GI Cancer Symposium in San Francisco, CA, to connect with global experts in gastrointestinal cancer care and explore advancements in early detection diagnostics.

Cizzle Bio will participate in the 43rd Annual J.P. Morgan Healthcare Conference, an exclusive event uniting global healthcare leaders, investors, and innovators to discuss advancements and partnerships in the healthcare sector.